On Monday, Shares of iBio, Inc. (NYSEMKT:IBIO), gained 5.71% to $1.13.
iBio, has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio’s proprietary anti-fibrosis products, IBIO-CFB03. Caliber’s production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03.
iBio is the exclusive worldwide license of the patents developed by Dr. Carol Feghali-Bostwick for therapies against fibrotic diseases. Dr. Feghali-Bostwick, the inventor of IBIO-CFB03, is collaborating with iBio for the development of various applications of her invention to address systemic sclerosis, idiopathic pulmonary fibrosis, and scleroderma. She is the Kitty Trask Holt Endowed Chair and Professor of Medicine in the Division of Rheumatology and Immunology at the Medical University of South Carolina where iBio anticipates the first human clinical trials of IBIO-CFB03 to be conducted.
The expansion in 2014 of iBio’s exclusive technology partnership with Novici Biotech LLC broadened iBio’s fibrosis therapeutics program through a combination of the strengths of iBio’s proprietary iBioLaunch™ platform technology with Novici’s patented optimization technology. iBio then engaged CBR International Corporation for planned regulatory and clinical services and assembled a Clinical Advisory Board of internationally recognized experts in fibrotic diseases to assist the company in clinical product development and human trial design.
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies comprise iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines.
At the end of Monday’s trade, Shares of SINA Corporation (NASDAQ:SINA), jumped 3.87% to $40.03.
Today, SINA Corporation declared that it has adopted a continuation of its previous shareholder rights plan.
The Company adopted the Continued Rights Plan to preserve, for the Company’s shareholders, the long-term value of the Company in the event of a potential takeover which appears to the Board of Directors of the Company to be coercive or unfair or otherwise not in the best interests of the Company and its shareholders. Initially, the rights to purchase ordinary shares of the Company will be represented by the Company’s ordinary share certificates, will not be traded separately from the ordinary shares and will not be exercisable.
The Rights will become exercisable only if a person or group obtains ownership of 10% or more of the Company’s ordinary shares or enters into an acquisition transaction at which time each Right would enable the holder of such Right to buy additional ordinary shares of the Company.
Generally, the Company may redeem the Rights for $0.001 per Right, subject to adjustment, or terminate the Continued Rights Plan at any time before (or within 10 business days following) the acquisition by a person or group of 10% or more of the Company’s ordinary shares.
SINA Corporation, through its auxiliaries, operates as an online media company in the People’s Republic of China. It operates SINA.com, an online brand advertising portal that provides region-focused format and content, counting multimedia news, sporting events news, automobile-related news, business news coverage and personal finance columns, entertainment news and events, technology updates, digital products reviews, luxury goods and services, collectibles, and video products, in addition to an interactive platform for fashion-conscious users to share comments and ideas on health, cosmetics, and beauty topics.
Horsehead Holding Corp. (NASDAQ:ZINC), ended its last trade with 3.77% gain, and closed at $14.58.
Horsehead, the parent company of Horsehead Corporation, The International Metals Reclamation Company, LLC and Zochem, Inc. plans to release its 2015 first quarter earnings before the market opens on Friday, May 8, 2015.
A conference call will be held on Friday, May 8, 2015 at 11:00 am ET to talk about the results. The call will be hosted by James Hensler, President & CEO, Robert Scherich, Vice President & CFO, and Gary Whitaker, Vice President, General Counsel & Secretary.
Horsehead Holding Corp., together with its auxiliaries, produces and sells zinc and nickel-based products primarily in the United States and Canada. The company operates through three segments: Horsehead, Zochem, and INMETCO. The Horsehead segment processes electric arc furnace dust and other zinc-bearing material to produce and sell zinc and other metals.
Finally, Scorpio Bulkers Inc. (NYSE:SALT), closed at $2.57, with 3.63% gain.
Scorpio Bulkers, declared that it has reached agreements to sell two Capesize newbuilding dry bulk vessels and an Ultramax new building dry bulk vessel for about $111 million in aggregate.
The Capesize vessels are presently being constructed in China and South Korea, and have predictable delivery dates between the third quarter of 2015 and the second quarter of 2016. The Ultramax vessel is presently being constructed in China and has an predictable delivery date in the first quarter of 2016.
Scorpio Bulkers Inc., together with its auxiliaries, engages in the marine transportation of dry bulk commodities. Its fleet transports a range of major and minor bulk commodities, counting ores, coal, grains, and fertilizers along worldwide shipping routes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
